Literature DB >> 23640995

Pharmacotherapy versus T lymphocytes for CMV.

Helen E Heslop1.   

Abstract

In this issue of Blood, Blyth et al report a phase 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderived cytomegalovirus (CMV)-specific cytotoxic T cells (CTLs) and compare outcomes with a group of concomitant controls who were transplanted at the trial centers but who did not receive CTLs.

Mesh：

Substances：

Year:  2013        PMID： 23640995      PMCID： PMC3643755          DOI： 10.1182/blood-2013-03-487249

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Naeem Khan; Malcolm Guiver; Paul A Moss; Stephen Mackinnon
Journal:  Lancet       Date:  2003-10-25       Impact factor: 79.321

2.  Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.

Authors:  Ann M Leen; G Doug Myers; Uluhan Sili; M Helen Huls; Heidi Weiss; Kathryn S Leung; George Carrum; Robert A Krance; Chung-Che Chang; Jeffrey J Molldrem; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Catherine M Bollard
Journal:  Nat Med       Date:  2006-09-24       Impact factor: 53.440

3.  Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.

Authors:  Emily Blyth; Leighton Clancy; Renee Simms; Chun K K Ma; Jane Burgess; Shivashni Deo; Karen Byth; Ming-Celine Dubosq; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Blood       Date:  2013-02-22       Impact factor: 22.113

4.  Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation.

Authors:  Tobias Feuchtinger; Kathrin Opherk; Wolfgang A Bethge; Max S Topp; Friedhelm R Schuster; Eva M Weissinger; Mohamad Mohty; Reuven Or; Michael Maschan; Michael Schumm; Klaus Hamprecht; Rupert Handgretinger; Peter Lang; Hermann Einsele
Journal:  Blood       Date:  2010-07-12       Impact factor: 22.113

5.  Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirus-specific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.

Authors:  Anita Schmitt; Torsten Tonn; Dirk H Busch; Götz Ulrich Grigoleit; Hermann Einsele; Marcus Odendahl; Lothar Germeroth; Mark Ringhoffer; Simone Ringhoffer; Markus Wiesneth; Jochen Greiner; Detlef Michel; Thomas Mertens; Markus Rojewski; Martin Marx; Stephanie von Harsdorf; Hartmut Döhner; Erhard Seifried; Donald Bunjes; Michael Schmitt
Journal:  Transfusion       Date:  2010-12-06       Impact factor: 3.157

6.  Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects.

Authors:  J Joseph Melenhorst; Ann M Leen; Catherine M Bollard; Máire F Quigley; David A Price; Cliona M Rooney; Malcolm K Brenner; A John Barrett; Helen E Heslop
Journal:  Blood       Date:  2010-08-13       Impact factor: 22.113

7.  Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation.

Authors:  Karl S Peggs; Kirsty Thomson; Edward Samuel; Gemma Dyer; Julie Armoogum; Ronjon Chakraverty; Kwok Pang; Stephen Mackinnon; Mark W Lowdell
Journal:  Clin Infect Dis       Date:  2011-01-01       Impact factor: 9.079

8.  Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy.

Authors:  Deepa Trivedi; Roxanne Y Williams; Richard J O'Reilly; Guenther Koehne
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

9.  Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones.

Authors:  S R Riddell; K S Watanabe; J M Goodrich; C R Li; M E Agha; P D Greenberg
Journal:  Science       Date:  1992-07-10       Impact factor: 47.728

10.  Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.

Authors:  Ulrike Gerdemann; Jacqueline M Keirnan; Usha L Katari; Ryu Yanagisawa; Anne S Christin; Leslie E Huye; Serena K Perna; Sravya Ennamuri; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney; Ann M Leen
Journal:  Mol Ther       Date:  2012-07-17       Impact factor: 11.454
  10 in total
  2 in total

1.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Authors:  Guenther Koehne; Aisha Hasan; Ekaterina Doubrovina; Susan Prockop; Eleanor Tyler; Gloria Wasilewski; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-29       Impact factor: 5.742

2.  Impact of early CMV reactivation in cord blood stem cell recipients in the current era.

Authors:  M Ramanathan; P Teira; M Battiwalla; J Barrett; K W Ahn; M Chen; J Green; M Laughlin; H M Lazarus; D Marks; A Saad; M Seftel; W Saber; B Savani; E K Waller; J Wingard; J J Auletta; C A Lindemans; M Boeckh; M L Riches
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.